Diabetes, Obesity and Metabolism
Responders Vs. Non‐Responders or How to Predict the Response to GLP ‐1 or GLP ‐1/ GIP Receptor Agonist Therapy
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual GLP‐1/GIP receptor agonists have transformed the pharmacological management of type 2 diabetes (T2D) and obesity, yet substantial interindividual variability in treatment response remains a defining clinical challenge. Methods Narrative review. PubMed was searched to 25 May 2026 (English language, human studies, 2005–2026) for biological, genetic, metabolic, hormonal, behavioural and psychosocial predictors of differential response. E …